RA
PBYI icon

Royce & Associates’s Puma Biotechnology PBYI Stock Holding History

Royce & Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,914
Closed -$70.9K – 800
2025
Q4 		$70.9K Sell
11,914
-6,811
-36% -$36.2K ﹤0.01% 755
2025
Q3 		$99.4K Buy
18,725
+1,440
+8% +$6.11K ﹤0.01% 752
2025
Q2 		$59.3K Sell
17,285
-1,440
-8% -$4.6K ﹤0.01% 774
2025
Q1 		$55.4K Hold
18,725
– – ﹤0.01% 786
2024
Q4 		$57.1K Sell
18,725
-1,440
-7% -$4.19K ﹤0.01% 823
2024
Q3 		$51.4K Buy
20,165
+8,427
+72% +$25.5K ﹤0.01% 858
2024
Q2 		$38.3K Hold
11,738
– – ﹤0.01% 868
2024
Q1 		$62.2K Buy
+11,738
New +$63.2K ﹤0.01% 868
2020
Q3 		– Sell
-1,890
Closed -$20K – 1127
2020
Q2 		$20K Buy
1,890
+42
+2% +$435 ﹤0.01% 1116
2020
Q1 		$16K Buy
+1,848
New +$18K ﹤0.01% 1108
2019
Q4 		– Sell
-1,749
Closed -$19K – 1164
2019
Q3 		$19K Buy
+1,749
New +$18.9K ﹤0.01% 1113

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Royce & Associates's PBYI Position: Q1 2026 in Review

Royce & Associates sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 11,914 shares — an estimated $70.9K sold.

Royce & Associates first reported a position in PBYI in Q3 2019 and held it in 11 quarters. The position peaked at $99.4K in Q3 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Royce & Associates reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Royce & Associates sold 11,914 Puma Biotechnology shares in Q1 2026, an estimated $70.9K.
  • Royce & Associates first reported a position in Puma Biotechnology in Q3 2019 and held it in 11 quarters.
  • Royce & Associates's Puma Biotechnology position peaked at $99.4K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.